Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rubella vaccine, live is a live-attenuated viral vaccine primarily derived from the Wistar Institute RA 27/3 strain of the rubella virus. It is indicated for active immunization to prevent rubella (German measles) and is critical in preventing congenital rubella syndrome in newborns when administered to women of childbearing age prior to pregnancy. The vaccine works by inducing the production of specific neutralizing antibodies and stimulating a cell-mediated immune response against the rubella virus. While available as a monovalent product (e.g., Meruvax II), it is most frequently administered as a component of combination vaccines such as MMR (measles, mumps, and rubella). Recent developments include the creation of serum-free formulations and needle-free delivery systems to improve global access and safety.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rubella vaccine, live.